Oncogenic transcription factors and neogenes: New opportunities for cancer immunotherapy?

Elizabeth W Abrash¹, J Mauro Calabrese²

Affiliations

¹ Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; RNA Discovery Center, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA.
² Department of Pharmacology, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; RNA Discovery Center, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA. Electronic address: jmcalabr@med.unc.edu.

PMID: 35803214
DOI: 10.1016/j.molcel.2022.06.006

Comment

Oncogenic transcription factors and neogenes: New opportunities for cancer immunotherapy?

Elizabeth W Abrash et al. Mol Cell. 2022.

. 2022 Jul 7;82(13):2353-2355.

doi: 10.1016/j.molcel.2022.06.006.

Authors

Elizabeth W Abrash¹, J Mauro Calabrese²

Affiliations

¹ Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; RNA Discovery Center, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA.
² Department of Pharmacology, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; RNA Discovery Center, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 120 Mason Farm Road, Chapel Hill, NC 27599, USA. Electronic address: jmcalabr@med.unc.edu.

PMID: 35803214
DOI: 10.1016/j.molcel.2022.06.006

Abstract

Vibert et al. (2022) demonstrate that oncogenic transcription factor fusion proteins bind otherwise silent genomic regions, producing RNAs that can be spliced, exported, and translated. These "neogenes" represent possible targets for immunotherapy and may even be universal byproducts of altered transcription in cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Comment on

Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions.
Vibert J, Saulnier O, Collin C, Petit F, Borgman KJE, Vigneau J, Gautier M, Zaidi S, Pierron G, Watson S, Gruel N, Hénon C, Postel-Vinay S, Deloger M, Raynal V, Baulande S, Laud-Duval K, Hill V, Grossetête S, Dingli F, Loew D, Torrejon J, Ayrault O, Orth MF, Grünewald TGP, Surdez D, Coulon A, Waterfall JJ, Delattre O. Vibert J, et al. Mol Cell. 2022 Jul 7;82(13):2458-2471.e9. doi: 10.1016/j.molcel.2022.04.019. Epub 2022 May 11. Mol Cell. 2022. PMID: 35550257

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Oncogenic transcription factors and neogenes: New opportunities for cancer immunotherapy?

Affiliations

Oncogenic transcription factors and neogenes: New opportunities for cancer immunotherapy?

Authors

Affiliations

Abstract

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

Grants and funding